22nd Century Group, Inc. (NYSE: XXII), a plant biotechnology company, focuses on tobacco harm reduction and smoking cessation products produced from modifying the nicotine content in tobacco plants through genetic engineering and plant breeding. It develops smoking cessation products for smokers who are unable or unwilling to quit smoking; and modified risk tobacco products that reduce exposure to certain tobacco smoke toxins compared to conventional cigarettes. For more information, visit the company’s website at www.xxiicentury.com